<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00703391</url>
  </required_header>
  <id_info>
    <org_study_id>D0520C00002</org_study_id>
    <nct_id>NCT00703391</nct_id>
  </id_info>
  <brief_title>A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <official_title>A 2-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Tolerability and Pharmacokinetics of Orally Administered AZD9668 in Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the tolerability (effect of drug on body) and
      pharmacokinetics (effect of body on drug) of AZD9668 in patients with mild to moderate COPD
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alanine Aminotransferase (ALT)</measure>
    <time_frame>Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)</time_frame>
    <description>ALT level greater than 3 times the upper limit of normal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate Aminotransferase (AST)</measure>
    <time_frame>Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)</time_frame>
    <description>AST level greater than 3 times the upper limit of normal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Creatine Kinase (CK)</measure>
    <time_frame>Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)</time_frame>
    <description>Change from baseline to Day 14</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Bilirubin</measure>
    <time_frame>Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)</time_frame>
    <description>Change from baseline to Day 14</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Creatinine</measure>
    <time_frame>Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)</time_frame>
    <description>Creatinine level greater than the upper limit of normal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Haemoglobin (Hb)</measure>
    <time_frame>Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)</time_frame>
    <description>Change from baseline to Day 14</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reticulocytes</measure>
    <time_frame>Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)</time_frame>
    <description>Change from baseline to Day 14</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leucocytes</measure>
    <time_frame>Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)</time_frame>
    <description>Change from baseline to Day 14</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QTcF (QT Interval Corrected for Heart Rate by Fridericia's Method)</measure>
    <time_frame>Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)</time_frame>
    <description>QTcF interval greater than 450 ms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QTcF</measure>
    <time_frame>Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)</time_frame>
    <description>QTcF change from baseline greater than 60 ms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV1 (Forced Expiratory Volume in the First Second)</measure>
    <time_frame>Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)</time_frame>
    <description>Change from baseline to Day 14</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours Post-dose (AUC(0-12))</measure>
    <time_frame>Pre-dose on day -1 to day 15 (end of dosing)</time_frame>
    <description>AUC(0-12) following 14 days' dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Peak or Maximum Plasma Concentration Following Drug Administration (Cmax)</measure>
    <time_frame>Pre-dose on day -1 to day 15 (end of dosing)</time_frame>
    <description>Cmax following 14 days' dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Observed Peak or Maximum Concentration Following Oral Drug Administration (Tmax)</measure>
    <time_frame>Pre-dose on day -1 to day 15 (end of dosing)</time_frame>
    <description>tmax following 14 days' dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-life of Drug in Plasma (t1/2)</measure>
    <time_frame>Pre-dose on day -1 to day 15 (end of dosing)</time_frame>
    <description>t1/2 following 14 days' dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance of Drug From Plasma (CLR)</measure>
    <time_frame>Pre-dose on day -1 to day 15 (end of dosing)</time_frame>
    <description>CLR following 14 days' dosing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sputum Absolute Neutrophil Count</measure>
    <time_frame>Pre-dose day -1 to post-dose on day 14</time_frame>
    <description>Change from baseline to Day 14 in absolute neutrophil count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum Differential Neutrophil Count</measure>
    <time_frame>Pre-dose day -1 to post-dose on day 14</time_frame>
    <description>Change from baseline to Day 14 in percentage neutrophil count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AZD9668 Sputum Concentrations</measure>
    <time_frame>Pre-dose day -1 to post-dose on day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative Sputum Bacteriology</measure>
    <time_frame>Pre-dose day -1 to post-dose on day 15</time_frame>
    <description>Number of patients with an increase in bacteriological count from Day -1 to Day 15</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9668</intervention_name>
    <description>30mg oral tablets twice daily (bid) for 14 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo to 30mg oral tablet twice daily (bid) for 14 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild to moderate COPD

          -  Smokers or ex-smokers

          -  post-menopausal females

        Exclusion Criteria:

          -  Past history or current evidence of clinically significant heart disease

          -  Lung disease other than COPD

          -  Treatment with systemic steroids within 8 weeks of study visit 2

          -  Treatment with antibiotics within 4 weeks of study visit 1 or study visit 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristina Panke</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel International GmbhH (CRO)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2008</study_first_submitted>
  <study_first_submitted_qc>June 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2008</study_first_posted>
  <results_first_submitted>November 30, 2010</results_first_submitted>
  <results_first_submitted_qc>November 30, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 29, 2010</results_first_posted>
  <last_update_submitted>January 24, 2012</last_update_submitted>
  <last_update_submitted_qc>January 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic</keyword>
  <keyword>obstructive</keyword>
  <keyword>pulmonary</keyword>
  <keyword>lung</keyword>
  <keyword>respiratory disease</keyword>
  <keyword>tolerability</keyword>
  <keyword>placebo-controlled</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient enrolled: 11 June 2008. Last patient completed: 09 October 2008. Single-centre study performed at a Clinical Pharmacology Unit</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD9668</title>
          <description>AZD9668 2x30mg oral tablets twice daily (bid) for 14 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matched placebo tablets twice daily (bid) for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD9668</title>
          <description>AZD9668 2x30mg oral tablets twice daily (bid) for 14 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matched placebo tablets twice daily (bid) for 14 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.6" lower_limit="42" upper_limit="70"/>
                    <measurement group_id="B2" value="52.8" lower_limit="44" upper_limit="65"/>
                    <measurement group_id="B3" value="56" lower_limit="42" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Alanine Aminotransferase (ALT)</title>
        <description>ALT level greater than 3 times the upper limit of normal</description>
        <time_frame>Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg oral tablets twice daily (bid) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo tablets twice daily (bid) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase (ALT)</title>
          <description>ALT level greater than 3 times the upper limit of normal</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aspartate Aminotransferase (AST)</title>
        <description>AST level greater than 3 times the upper limit of normal</description>
        <time_frame>Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg oral tablets twice daily (bid) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo tablets twice daily (bid) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST)</title>
          <description>AST level greater than 3 times the upper limit of normal</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Creatine Kinase (CK)</title>
        <description>Change from baseline to Day 14</description>
        <time_frame>Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg oral tablets twice daily (bid) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo tablets twice daily (bid) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Creatine Kinase (CK)</title>
          <description>Change from baseline to Day 14</description>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" spread="19.260"/>
                    <measurement group_id="O2" value="-69.57" spread="141.383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Bilirubin</title>
        <description>Change from baseline to Day 14</description>
        <time_frame>Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg oral tablets twice daily (bid) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo tablets twice daily (bid) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Total Bilirubin</title>
          <description>Change from baseline to Day 14</description>
          <units>micromol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="2.124"/>
                    <measurement group_id="O2" value="-0.28" spread="2.563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Creatinine</title>
        <description>Creatinine level greater than the upper limit of normal</description>
        <time_frame>Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg oral tablets twice daily (bid) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo tablets twice daily (bid) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine</title>
          <description>Creatinine level greater than the upper limit of normal</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Haemoglobin (Hb)</title>
        <description>Change from baseline to Day 14</description>
        <time_frame>Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg oral tablets twice daily (bid) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo tablets twice daily (bid) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Haemoglobin (Hb)</title>
          <description>Change from baseline to Day 14</description>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="4.73"/>
                    <measurement group_id="O2" value="-0.2" spread="6.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Reticulocytes</title>
        <description>Change from baseline to Day 14</description>
        <time_frame>Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg oral tablets twice daily (bid) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo tablets twice daily (bid) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Reticulocytes</title>
          <description>Change from baseline to Day 14</description>
          <units>relative particle count (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="2.851"/>
                    <measurement group_id="O2" value="1.73" spread="1.605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Leucocytes</title>
        <description>Change from baseline to Day 14</description>
        <time_frame>Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg oral tablets twice daily (bid) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo tablets twice daily (bid) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Leucocytes</title>
          <description>Change from baseline to Day 14</description>
          <units>10**9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.001" spread="0.8816"/>
                    <measurement group_id="O2" value="0.265" spread="0.4657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>QTcF (QT Interval Corrected for Heart Rate by Fridericia’s Method)</title>
        <description>QTcF interval greater than 450 ms</description>
        <time_frame>Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg oral tablets twice daily (bid) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo tablets twice daily (bid) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>QTcF (QT Interval Corrected for Heart Rate by Fridericia’s Method)</title>
          <description>QTcF interval greater than 450 ms</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>QTcF</title>
        <description>QTcF change from baseline greater than 60 ms</description>
        <time_frame>Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg oral tablets twice daily (bid) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo tablets twice daily (bid) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>QTcF</title>
          <description>QTcF change from baseline greater than 60 ms</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sputum Absolute Neutrophil Count</title>
        <description>Change from baseline to Day 14 in absolute neutrophil count</description>
        <time_frame>Pre-dose day -1 to post-dose on day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg oral tablets twice daily (bid) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo tablets twice daily (bid) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Absolute Neutrophil Count</title>
          <description>Change from baseline to Day 14 in absolute neutrophil count</description>
          <units>10**9/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4890" lower_limit="-1.439" upper_limit="0.439"/>
                    <measurement group_id="O2" value="-2.5645" lower_limit="-9.198" upper_limit="-0.283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sputum Differential Neutrophil Count</title>
        <description>Change from baseline to Day 14 in percentage neutrophil count</description>
        <time_frame>Pre-dose day -1 to post-dose on day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg oral tablets twice daily (bid) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo tablets twice daily (bid) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Differential Neutrophil Count</title>
          <description>Change from baseline to Day 14 in percentage neutrophil count</description>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="-11.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="-4.25" lower_limit="-9.0" upper_limit="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AZD9668 Sputum Concentrations</title>
        <time_frame>Pre-dose day -1 to post-dose on day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg oral tablets twice daily (bid) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo tablets twice daily (bid) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>AZD9668 Sputum Concentrations</title>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7" lower_limit="26.5" upper_limit="64.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantitative Sputum Bacteriology</title>
        <description>Number of patients with an increase in bacteriological count from Day -1 to Day 15</description>
        <time_frame>Pre-dose day -1 to post-dose on day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg oral tablets twice daily (bid) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo tablets twice daily (bid) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Quantitative Sputum Bacteriology</title>
          <description>Number of patients with an increase in bacteriological count from Day -1 to Day 15</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>FEV1 (Forced Expiratory Volume in the First Second)</title>
        <description>Change from baseline to Day 14</description>
        <time_frame>Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg oral tablets twice daily (bid) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo tablets twice daily (bid) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 (Forced Expiratory Volume in the First Second)</title>
          <description>Change from baseline to Day 14</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.039" spread="0.2173"/>
                    <measurement group_id="O2" value="-0.110" spread="0.3043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours Post-dose (AUC(0-12))</title>
        <description>AUC(0-12) following 14 days' dosing</description>
        <time_frame>Pre-dose on day -1 to day 15 (end of dosing)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg oral tablets twice daily (bid) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo tablets twice daily (bid) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours Post-dose (AUC(0-12))</title>
          <description>AUC(0-12) following 14 days' dosing</description>
          <units>nM.h</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7560" lower_limit="5820" upper_limit="9570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Observed Peak or Maximum Plasma Concentration Following Drug Administration (Cmax)</title>
        <description>Cmax following 14 days' dosing</description>
        <time_frame>Pre-dose on day -1 to day 15 (end of dosing)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg oral tablets twice daily (bid) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo tablets twice daily (bid) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Peak or Maximum Plasma Concentration Following Drug Administration (Cmax)</title>
          <description>Cmax following 14 days' dosing</description>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1420" lower_limit="1030" upper_limit="1930"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Observed Peak or Maximum Concentration Following Oral Drug Administration (Tmax)</title>
        <description>tmax following 14 days' dosing</description>
        <time_frame>Pre-dose on day -1 to day 15 (end of dosing)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg oral tablets twice daily (bid) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo tablets twice daily (bid) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Observed Peak or Maximum Concentration Following Oral Drug Administration (Tmax)</title>
          <description>tmax following 14 days' dosing</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit="0.490" upper_limit="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Half-life of Drug in Plasma (t1/2)</title>
        <description>t1/2 following 14 days' dosing</description>
        <time_frame>Pre-dose on day -1 to day 15 (end of dosing)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg oral tablets twice daily (bid) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo tablets twice daily (bid) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life of Drug in Plasma (t1/2)</title>
          <description>t1/2 following 14 days' dosing</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.89" lower_limit="5.00" upper_limit="6.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Renal Clearance of Drug From Plasma (CLR)</title>
        <description>CLR following 14 days' dosing</description>
        <time_frame>Pre-dose on day -1 to day 15 (end of dosing)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg oral tablets twice daily (bid) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo tablets twice daily (bid) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance of Drug From Plasma (CLR)</title>
          <description>CLR following 14 days' dosing</description>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.13" lower_limit="3.49" upper_limit="8.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD9668</title>
          <description>AZD9668 2x30mg oral tablets twice daily (bid) for 14 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matched placebo tablets twice daily (bid) for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5"/>
                <counts group_id="E2" subjects_affected="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

